Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Hemodialysis Fistula-Related Ischemic Neuropathy in End-Stage Renal Failure: An Electrophysiological Study A Single Study in Assiut University Hospital (Hemodialysis)

16 november 2026 uppdaterad av: Shimaa Salah Ali

Hemodialysis Fistula-Related Ischemic Neuropathy in End-Stage Renal Failure: An Electrophysiological Study A single study in Assiut university hospital

Studieöversikt

Status

Har inte rekryterat ännu

Detaljerad beskrivning

End-stage renal failure (ESRF) represents a major global health burden, with hemodialysis being the most common renal replacement therapy. The creation of an arteriovenous fistula (AVF) Is considered the preferred vascular access for long-term hemodialysis due to its superior patency and lower complication rates compared to grafts and catheters (1-2) Despite its advantages, AVF creation may be associated with several complications, including ischemic steal syndrome and ischemic monomelic neuropathy (IMN). Ischemic neuropathy is a rare but potentially disabling complication resulting from acute or chronic ischemia of peripheral nerves following AVF creation. Patients may present with severe pain, sensory disturbances, weakness, and functional impairment of the affected limb (3-5) Early diagnosis remains challenging because symptoms may overlap with uremic neuropathy, diabetic neuropathy, and other peripheral nerve disorders commonly encountered in ESRF patients. Electrophysiological studies, including nerve conduction studies (NCS) and electromyography (EMG), provide objective assessment of nerve dysfunction and may facilitate early diagnosis and differentiation from other neuropathic conditions Limited data are available regarding the electrophysiological characteristics of AVF-related ischemic neuropathy, particularly in ESRF populations. Therefore, a comprehensive electrophysiological evaluation may contribute to improved recognition, management, and prevention of long-term disability

Hemodialysis fistula-related ischemic neuropathy is an under-recognized complication in patients with ESRF. Delayed diagnosis may lead to irreversible neurological deficits and impaired quality of life. The electrophysiological features and associated risk factors remain insufficiently characterized in many dialysis populations

This study aims to provide a detailed electrophysiological assessment of ischemic neuropathy associated with AVF creation in ESRF patients. The findings may facilitate early diagnosis, improve clinical outcomes, and contribute to developing screening and management strategies for high-risk patients

Aim of the Work:

To evaluate electrophysiological abnormalities associated with hemodialysis fistula-related ischemic neuropathy in patients with end-stage renal failure

  • Primary Objective To assess peripheral nerve function using nerve conduction studies and electromyography in ESRF patients with AVF-related ischemic neuropathy
  • Secondary Objectives To compare electrophysiological findings between ESRF patients with and without ischemic neuropathy To identify clinical and vascular factors associated with the development of ischemic neuropathy To determine the severity and distribution of nerve involvement To correlate electrophysiological findings with clinical manifestations and duration of AVF use

Patients and methods:

Type of the study: Analytical Cross-Sectional Case-Control Study Study Setting: The study will be conducted at Nephrology and Hemodialysis Unit at Assuit University hospital

Study duration: august 2026 - august 2027 Study populations: Patients diagnosed with end-stage renal failure undergoing maintenance hemodialysis through an arteriovenous fistula Group I (Cases) ESRF patients with clinical evidence of AVF-related ischemic neuropathy Group II (Controls)

  • ESRF patients with functioning AVFs but without clinical evidence of ischemic neuropathy
  • Presence of AVF
  • Clinical manifestations suggestive of ischemic neuropathy after AVF creation
  • Ability to provide informed consent ESRF patients on maintenance hemodialysis via AVF. No symptoms or signs of ischemic neuropathy Inclusion Criteria Age ≥18 years Diagnosed ESRF on regular hemodialysis Exclusion Criteria Pre-existing hereditary neuropathies Cervical radiculopathy Brachial plexopathy Motor neuron disease. Recent upper limb trauma. Peripheral nerve entrapment syndromes. Severe cognitive impairment. Refusal to participate

Methodology A. Clinical Assessment

All participants will undergo:

Detailed medical history, Dialysis history

AVF characteristics:

Site of fistula Duration since creation Side of fistula Previous vascular interventions

Neurological examination:

Motor assessment Sensory assessment Deep tendon reflexes Muscle strength grading using MRC scale B. Laboratory Investigations Complete blood count (CBC) Serum creatinine Blood urea nitrogen (BUN) Electrolytes HbA1c (for diabetic patients) Serum albumin Calcium and phosphorus levels C. Vascular Assessment Duplex Doppler ultrasonography of AVF Assessment of arterial flow and steal phenomenon D. Electrophysiological Assessment

Nerve Conduction Studies (NCS):

Electromyography (EMG)

Studietyp

Observationell

Inskrivning (Beräknad)

50

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

1 år och äldre (Barn, Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Testmetod

Sannolikhetsprov

Studera befolkning

: Patients diagnosed with end-stage renal failure undergoing maintenance hemodialysis through an arteriovenous fistula Group I (Cases) ESRF patients with clinical evidence of AVF-related ischemic neuropathy Group II (Controls)

  • ESRF patients with functioning AVFs but without clinical evidence of ischemic neuropathy
  • Presence of AVF
  • Clinical manifestations suggestive of ischemic neuropathy after AVF creation
  • Ability to provide informed consent ESRF patients on maintenance hemodialysis via AVF. No symptoms or signs of ischemic neuropathy

Beskrivning

Inclusion Criteria:

  • Age ≥18 years
  • Diagnosed ESRF on regular hemodialysis

Exclusion Criteria:

  • Pre-existing hereditary neuropathies
  • Cervical radiculopathy
  • Brachial plexopathy
  • Motor neuron disease.
  • Recent upper limb trauma.
  • Peripheral nerve entrapment syndromes.
  • Severe cognitive impairment.
  • Refusal to participate

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: OTHER
  • Tidsperspektiv: PROSPECTIVE

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Motor Nerve Conduction Velocity
Tidsram: Up to 1 year post-AVF creation

Assessed by Nerve Conduction Studies on the upper limb with the arteriovenous fistula . Measured in meters per second.

Up to 1 year post-AVF creation
Arteriovenous Fistula Blood Flow Volume
Tidsram: Up to 1 year post-AVF creation

Assessed by Duplex Doppler Ultrasound on the arteriovenous fistula. Measured in milliliters per minute.

Up to 1 year post-AVF creation

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Sensory Nerve Conduction Velocity
Tidsram: Up to 1 year post-AVF creation

Assessed by Nerve Conduction Studies on the upper limb with the arteriovenous fistula . Measured in meters per second

Up to 1 year post-AVF creation

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Samarbetspartners

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

4 november 2026

Primärt slutförande (Beräknad)

1 januari 2028

Avslutad studie (Beräknad)

1 januari 2028

Studieregistreringsdatum

Först inskickad

4 november 2026

Först inskickad som uppfyllde QC-kriterierna

16 november 2026

Första postat (Faktisk)

20 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

20 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

16 november 2026

Senast verifierad

1 oktober 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

OBESLUTSAM

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera